Reply: Due to the lack of significant mortality benefits along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged.
作者信息
Werner Gerald S, Hildick-Smith David, Trial Investigators For The EuroCTO
机构信息
Klinikum Darmstadt GmbH, Darmstadt, Germany.
Sussex Cardiac Centre, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.
出版信息
EuroIntervention. 2024 Jan 1;20(1):110. doi: 10.4244/EIJ-D-23-00857.
Abstract
摘要
相似文献
1
Reply: Due to the lack of significant mortality benefits along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged.
EuroIntervention. 2024 Jan 1;20(1):110. doi: 10.4244/EIJ-D-23-00857.
2
Letter: Due to the lack of significant mortality benefit along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged.
EuroIntervention. 2024 Jan 1;20(1):109. doi: 10.4244/EIJ-D-23-00830.
3
Percutaneous coronary intervention in chronic total occlusions: Should it be avoided in type 2 diabetic patients?
Rev Port Cardiol. 2024 Apr;43(4):175-176. doi: 10.1016/j.repc.2023.12.005. Epub 2023 Dec 29.
4
Endothelial Avulsion of the Septal Branch During Retrograde Chronic Total Occlusion Intervention.
Cardiovasc Revasc Med. 2021 Jul;28S:219-221. doi: 10.1016/j.carrev.2021.02.021. Epub 2021 Mar 2.
5
Fully Transradial Versus Transfemoral Approach for Percutaneous Intervention of Coronary Chronic Total Occlusions Applying the Hybrid Algorithm: Insights From RECHARGE Registry.
Circ Cardiovasc Interv. 2017 Sep;10(9). doi: 10.1161/CIRCINTERVENTIONS.117.005255.
6
Randomized Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusions: The CrossBoss First Trial.
JACC Cardiovasc Interv. 2018 Feb 12;11(3):225-233. doi: 10.1016/j.jcin.2017.10.023.
7
Assessment of the OPEN-CLEAN Chronic Total Occlusion Percutaneous Coronary Intervention Perforation Score in the PROGRESS-CTO Registry.
Cardiovasc Revasc Med. 2022 Oct;43:138-139. doi: 10.1016/j.carrev.2022.04.012. Epub 2022 Apr 25.
8
Impact of coronary collaterals on the outcomes of chronic total occlusion percutaneous coronary intervention.
J Invasive Cardiol. 2023 Nov;35(11). doi: 10.25270/jic/23.00233.
9
Vascular Access in Percutaneous Coronary Intervention of Chronic Total Occlusions: A State-of-the-Art Review.
Circ Cardiovasc Interv. 2023 Aug;16(8):e013009. doi: 10.1161/CIRCINTERVENTIONS.123.013009. Epub 2023 Jul 17.
10
Heartbeat: The ongoing controversy of intervention for chronic total coronary occlusions.
Heart. 2018 Sep;104(17):1385-1387. doi: 10.1136/heartjnl-2018-313921.
本文引用的文献
1
Letter: Due to the lack of significant mortality benefit along with high procedural complication rates, percutaneous coronary intervention of chronic total occlusions should be discouraged.
EuroIntervention. 2024 Jan 1;20(1):109. doi: 10.4244/EIJ-D-23-00830.
2
Three-year outcomes of A Randomized Multicentre Trial Comparing Revascularization and Optimal Medical Therapy for Chronic Total Coronary Occlusions (EuroCTO).
EuroIntervention. 2023 Sep 18;19(7):571-579. doi: 10.4244/EIJ-D-23-00312.
3
Percutaneous Coronary Intervention of Chronic Total Occlusion Associated with Higher Inpatient Mortality and Complications Compared With Non-CTO Lesions.
Am J Med. 2023 Oct;136(10):994-999. doi: 10.1016/j.amjmed.2023.06.004. Epub 2023 Jun 24.
4
Recanalisation of coronary chronic total occlusions.
EuroIntervention. 2022 Sep 20;18(7):535-561. doi: 10.4244/EIJ-D-21-01117.
5
Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study).
Cardiol Ther. 2017 Jun;6(1):81-88. doi: 10.1007/s40119-016-0081-3. Epub 2017 Jan 2.
6
Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry).
JACC Cardiovasc Interv. 2015 Feb;8(2):245-253. doi: 10.1016/j.jcin.2014.08.014.
7
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
JAMA. 2004 Jan 21;291(3):309-16. doi: 10.1001/jama.291.3.309.
Zotero 插件